Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents

被引:7
作者
Bloch, Meital [1 ]
Jablonowski, Lauren [2 ]
Yavin, Eylon [1 ]
Moradov, Dorit [1 ]
Djavsarov, Irena [1 ]
Nyska, Abraham
Wheatley, Margaret [2 ]
Rubinstein, Abraham [1 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Inst Drug Res, IL-91120 Jerusalem, Israel
[2] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA
关键词
Colon cancer; Real time diagnosis; Cationized polyacrylamide; Recognition peptide; Ultrasound; Microbubbles; COLORECTAL-CANCER; TRIGGERED DRUG; DELIVERY; MICROBUBBLES; GENE; DOXORUBICIN; PEPTIDE; DYSPLASIA; MARKER;
D O I
10.1016/j.ijpharm.2014.11.066
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To increase colonoscopy capability to discriminate benign from malignant polyps, we suggest combining two imaging approaches based on targeted polymeric platforms. Water-soluble cationized polyacrylamide (CPAA) was tagged with the near infrared (NIR) dye IR-783-S-Ph-COOH to form Flu-CPAA. The recognition peptide VRPMPLQ (reported to bind specifically to CRC tissues) was then conjugated with the Flu-CPAA to form Flu-CPAA-Pep which was then incorporated into echogenic microbubbles (MBs) made of polylactic acid (PLA) that are highly responsive to ultrasound. The ultimate design includes intravenous administration combined with local ultrasound and intra-colon inspection at the NIR range. In this proof of principle study PLA MBs were prepared by the double emulsion technique and loaded with several types of Flu-CPAA-Pep polymers. After insonation the submicron PLA fragments (SPF)-containing Flu-CPAA-Pep were examined in vitro for their ability to attach to colon cancer cells and in vivo (DMH induced rat model) for their ability to attach to colon malignant tissues and compared to the specific attachment of the free Flu-CPAA-Pep. The generation of SPF-containing Flu-CPAA-Pep resulted in a tissue attachment similar to that of the free, unloaded Flu-CPAA-Pep. The addition of VRPMPLQ to the polymeric backbone of the Flu-CPAA reduced cytotoxicity and improved the specific binding. (C) 2014 Published by Elsevier B.V.
引用
收藏
页码:504 / 516
页数:13
相关论文
共 43 条
[1]   Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery [J].
Amri, Ramzi ;
Bordeianou, Liliana G. ;
Sylla, Patricia ;
Berger, David L. .
JAMA SURGERY, 2013, 148 (08) :747-754
[2]   Ultrasound Molecular Imaging of Tumor Angiogenesis With an Integrin Targeted Microbubble Contrast Agent [J].
Anderson, Christopher R. ;
Hu, Xiaowen ;
Zhang, Hua ;
Tlaxca, Jose ;
Decleves, Anne-Emilie ;
Houghtaling, Robert ;
Sharma, Kumar ;
Lawrence, Michael ;
Ferrara, Katherine W. ;
Rychak, Joshua J. .
INVESTIGATIVE RADIOLOGY, 2011, 46 (04) :215-224
[3]  
[Anonymous], PROLIFERATIVE LESION
[4]  
[Anonymous], 1990, Pathol. Fisch. Rat., Ref. Atlas
[5]  
[Anonymous], MONOGRAPHS PATHOLOGY
[6]   The metastatic stage-dependent mucosal expression of sialic acid is a potential marker for targeting colon cancer with cationic polymers [J].
Azab, Abdel Kareem ;
Kleinstern, Jackie ;
Srebnik, Morris ;
Rubinstein, Abraham .
PHARMACEUTICAL RESEARCH, 2008, 25 (02) :379-386
[7]   The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide [J].
Bloch, Meital ;
Kam, Yossi ;
Yavin, Eylon ;
Moradov, Dorit ;
Nissan, Aviram ;
Ariel, Ilana ;
Rubinstein, Abraham .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (05) :904-913
[8]   A stimulus-responsive contrast agent for ultrasound molecular imaging [J].
Borden, Mark A. ;
Zhang, Hua ;
Gillies, Robert J. ;
Dayton, Paul A. ;
Ferrara, Katherine W. .
BIOMATERIALS, 2008, 29 (05) :597-606
[9]   High-speed optical observations of contrast agent destruction [J].
Bouakaz, A ;
Versluis, M ;
de Jong, N .
ULTRASOUND IN MEDICINE AND BIOLOGY, 2005, 31 (03) :391-399
[10]   Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery [J].
Cochran, Michael C. ;
Eisenbrey, John ;
Ouma, Richard O. ;
Soulen, Michael ;
Wheatley, Margaret A. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 414 (1-2) :161-170